In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined again by Dr. Paul Thielking.  Paul is a psychiatrist, palliative care physician, zen practitioner, and the chief scientific officer at Novamind. Paul joins the show to talk about psychedelic clinical trials.

(2:15) Introduction to the topic
(4:11) Cedar Clinical Research
(4:45) What is a clinical trial?
(10:42) The unique challenges of psychedelic clinical trials and regulating psychedelic-assisted psychotherapy
(15:09) Risk Evaluation and Mitigation Strategy (REMS)
(18:06) The therapy part of psychedelic-assisted therapy
(24:13) How important is integration support after psychedelic experience
(26:33) The resources required to do psychedelic-assisted therapy
(29:55) The challenges of training enough therapists to do psychedelic-assisted therapy 
(36:11) Psychedelic medicine accessibility and scaleability 
(39:25) Placebo-controlled double-blind psychedelic studies 
(44:02) Handling and accounting for disappointment when a trial participant gets the placebo
(49:11) Investigator initiated studies
(52:28) Compassionate use and expanded access
(55:45) What types of psychedelics are being studied in clinical trials

Email us questions and feedback at psychfrontiers@novamind.ca 
Learn more about our podcast at https://www.psychedelictherapyfrontiers.com/
Learn more about Novamind at https://www.novamind.ca/
Follow us on Instagram: 
https://www.instagram.com/drstevethayer/
https://www.instagram.com/innerspacedoctor/
https://www.instagram.com/novamind_inc/